ロード中...
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
BACKGROUND: Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and safety of...
保存先:
| 出版年: | Respir Res |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6194688/ https://ncbi.nlm.nih.gov/pubmed/30340638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0907-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|